Clinical trial • Not applicable • Musculoskeletal

Autologous adipose-derived mesenchymal stem cells in vitro expanded for Degenerative disc disease

Not applicable trial of Autologous adipose-derived mesenchymal stem cells in vitro expanded for Degenerative disc disease.

Overview

Trial Therapeutic Area
Musculoskeletal
Trial Disease
Degenerative disc disease
Trial Stage
Not applicable
Drug Modality
Cell therapy

Key dates

Initial CTIS Submission Date
30-09-2024
First CTIS Authorization Date
15-10-2024

Trial design

Randomised, control group: sham operation — a needle skin puncture is performed on the back to imitate the intradiscal injection. Not applicable trial across 1 site in Denmark.

Randomised
Yes
Comparator
Control group: sham operation — a needle skin puncture is performed on the back to imitate the intradiscal injection.
Target Sample Size
34
Trial Duration For Participant
730

Eligibility

Recruits 34 No vulnerable populations selected; informed consent forms provided (documents: L1_Informed Consent Form, L1_SubjectInformationSheet_redacted)..

Pregnancy Exclusion
Pregnancy or breastfeeding.
Vulnerable Population
No vulnerable populations selected; informed consent forms provided (documents: L1_Informed Consent Form, L1_SubjectInformationSheet_redacted).

Inclusion criteria

  • {"criterion_text":"- Patients with lumbar back pain (max 2 levels)\n- age 20 to 60 yrs,\n- moderate disc degeneration (Pfirman grade 2-3)"}

Exclusion criteria

  • {"criterion_text":"- Patients with lumbar back pain of other apparent reason such as: severe spinal stenosis, herniated disc, spondylolisthesis grade 2 or more.\n- Penicillin allergies.\n- Age <20yrs, >60 yrs.\n- Cognitive impairment.\n- Treatment with cytostatic drugs.\n- High risk of bleeding (bleeding disorder, taking anticoagulants etc.).\n- Previous injections in disc.\n- Pregnancy or breastfeeding.\n- Conditions not compatible with MRI (non-compatible implants, claustrophobia, severe obesity).\n- Tumors, infection or fracture in spine."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Treatment success, pain reduction compared to control group Timeframe 2 yr, no post-intervention on treated level. No unexpected events by procedure.\n- VAS-score\n- pain diary\n- EQ-5D\n- ODI\n- SF-36\n- LBPRS","definition_or_measurement_approach":"- Treatment success: Timeframe 2 yr, no post-intervention on treated level. No unexpected events by procedure.\n- VAS-score: \n- pain diary: \n- EQ-5D: \n- ODI: \n- SF-36: \n- LBPRS: "}

Secondary endpoints

  • {"endpoint_text":"- MR morphology of disc: height, water content, fat and lipid, lactose, glucose, proteoglycans, collagen.","definition_or_measurement_approach":"- MR morphology of disc: height, water content, fat and lipid, lactose, glucose, proteoglycans, collagen."}

Recruitment

Planned Sample Size
34
Recruitment Window Months
31
Consent Approach
Informed consent obtained from participant; subject information and informed consent form documents available (L1_Informed Consent Form; L1_SubjectInformationSheet_redacted). No mention of assent or minor consent (participants are aged 20-60).

Geography

Total Number Of Sites
1
Total Number Of Participants
34

Denmark

Earliest CTIS Part Ii Submission Date
08-10-2024
Latest Decision Or Authorization Date
27-05-2025
Processing Time Days
231
Number Of Sites
1
Number Of Participants
34

Sites

Site Name
Aarhus Universitet (Vennelyst Boulevard 4, Aarhus C)
Department Name
Department of Orthopedic surgery
Contact Person Name
Haisheng Li
Contact Person Email
Haishli4@rm.dk

Sponsor

Primary sponsor

Full Name
Aarhus Universitet
Organisation Type
Educational Institution
Country Of Registered Address
Denmark

Third parties

  • {"country":"Denmark","full_name":"Aarhus Universitet","duties_or_roles":"Codes: 1,9","organisation_type":"Educational Institution"}
  • {"country":"Denmark","full_name":"Region Midtjylland","duties_or_roles":"Codes: 14,4","organisation_type":"Hospital/Clinic/Other health care facility"}

Investigational products

Investigational Product Name
MSC, adipose tissue
Active Substance
Autologous adipose-derived mesenchymal stem cells in vitro expanded
Modality
Cell therapy
Routes Of Administration
Intradiscal use
Route
Intradiscal
Authorisation Status
Unauthorised IMP (Advanced therapy medicinal product)
Starting Dose
20 million cells / 2 mL Ringer Acetate
Dose Levels
20 million cells / 2 mL (single dose)
Frequency
Single intradiscal injection

Related trials

Other published trials that may interest you.